Protocol Ledger

NCT05327296 · Phase III · COMPLETED

Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)

Interventional Phase III clinical trial protocol NCT05327296 sponsored by Sedana Medical in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-30 Enrollment: 282 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05327296
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)282 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05327296
Protocol FieldVerified Registry Value
NCT IdentifierNCT05327296
Consolidated Lead SponsorSedana Medical
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment282 participants (ACTUAL)
Registered Start Date2022-06-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI